[{"id":"ba5a9900-5311-4370-977a-05b3928feb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847453","created_at":"2021-04-19T12:52:34.348Z","updated_at":"2025-02-25T13:49:06.836Z","phase":"Phase 1","brief_title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","source_id_and_acronym":"NCT04847453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • MCL1 • BCL2L1 • SDC1 • BAX","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • MCL1 • BCL2L1 • SDC1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-20"},{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"b51da52a-9e40-4c55-9320-226cbd9d4846","acronym":"","url":"https://clinicaltrials.gov/study/NCT06105554","created_at":"2023-10-27T17:14:13.970Z","updated_at":"2025-02-25T15:21:01.076Z","phase":"Phase 1/2","brief_title":"Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06105554","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 08/31/2029","study_completion_date":" 08/31/2029","last_update_posted":"2025-02-12"},{"id":"825e707d-d24d-4a05-b786-1228f5cc02ad","acronym":"Window-2","url":"https://clinicaltrials.gov/study/NCT03710772","created_at":"2021-01-18T18:11:30.804Z","updated_at":"2025-02-25T15:34:12.058Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT03710772 - Window-2","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • CD20 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2025","study_completion_date":" 05/22/2025","last_update_posted":"2025-02-11"},{"id":"9bf88391-bf8e-4bd2-b27f-b745a3c4ca24","acronym":"ECOG-ACRIN E1910","url":"https://clinicaltrials.gov/study/NCT02003222","created_at":"2021-01-18T09:08:51.217Z","updated_at":"2025-02-25T16:36:18.435Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02003222 - ECOG-ACRIN E1910","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1","pipe":"","alterations":" ","tags":["ABL1 • BCR • CDKN2A • RUNX1 • IGH • ETV6 • CD4 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 488","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 06/23/2023","primary_completion_date":" 06/23/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-06"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"facf7f83-63bf-49f3-a6fb-2b75c0782dba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848687","created_at":"2023-05-08T15:04:02.177Z","updated_at":"2025-02-25T17:26:10.730Z","phase":"Phase 1/2","brief_title":"TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II","source_id_and_acronym":"NCT05848687","lead_sponsor":"Tanja Andrea Gruber","biomarkers":" KMT2A","pipe":" | ","alterations":" CD19 positive","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Blincyto (blinatumomab) • Zolinza (vorinostat) • dexamethasone • mitoxantrone • Komzifti (ziftomenib) • mercaptopurine"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2025-01-31"},{"id":"babb040a-8e58-46a5-a8a3-a326e81d8c49","acronym":"MORAb-202-G000-201","url":"https://clinicaltrials.gov/study/NCT04300556","created_at":"2021-01-18T20:51:39.021Z","updated_at":"2025-02-25T14:29:08.502Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","source_id_and_acronym":"NCT04300556 - MORAb-202-G000-201","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • BRAF • ER • ALK • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRAF • ER • ALK • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003) • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 08/06/2020","start_date":" 08/06/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-12-09"},{"id":"1f9f32bf-38be-4d03-93bd-0c9d5a3ca2cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03740334","created_at":"2022-04-24T08:59:42.482Z","updated_at":"2025-02-25T15:43:17.223Z","phase":"Phase 1","brief_title":"Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL","source_id_and_acronym":"NCT03740334","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 03/04/2023","primary_completion_date":" 03/04/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-10-24"},{"id":"8f093304-44ac-4ac6-aa1f-9424e042581c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494882","created_at":"2021-01-18T12:01:48.985Z","updated_at":"2025-02-25T15:42:29.508Z","phase":"Phase 1","brief_title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","source_id_and_acronym":"NCT02494882","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R","tags":["ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Jakafi (ruxolitinib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-07-29"},{"id":"61e57503-680e-4667-ac9e-45a1209fdaaf","acronym":"TT4B","url":"https://clinicaltrials.gov/study/NCT00734877","created_at":"2021-01-18T02:46:06.475Z","updated_at":"2025-02-25T14:55:10.781Z","phase":"Phase 3","brief_title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","source_id_and_acronym":"NCT00734877 - TT4B","lead_sponsor":"University of Arkansas","biomarkers":" TP53","pipe":" | ","alterations":" TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dexamethasone • thalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-07-03"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"f788184e-3946-4215-8882-b92922df8fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436707","created_at":"2021-01-18T11:40:02.216Z","updated_at":"2024-07-02T16:34:26.702Z","phase":"Phase 2","brief_title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","source_id_and_acronym":"NCT02436707","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 10/27/2015","start_date":" 10/27/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"8e23dfed-66db-4dea-b013-38aff34edc35","acronym":"NCI-2015-00960","url":"https://clinicaltrials.gov/study/NCT02427620","created_at":"2021-01-17T17:51:13.234Z","updated_at":"2024-07-02T16:34:36.739Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT02427620 - NCI-2015-00960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • CD20","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • MYC • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-10"},{"id":"9dcb826a-6f40-4c36-9dae-a741f622b8ee","acronym":"DREAMM-3","url":"https://clinicaltrials.gov/study/NCT04162210","created_at":"2021-01-18T20:17:55.897Z","updated_at":"2024-07-02T16:34:36.734Z","phase":"Phase 3","brief_title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","source_id_and_acronym":"NCT04162210 - DREAMM-3","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 04/02/2020","start_date":" 04/02/2020","primary_txt":" Primary completion: 09/12/2022","primary_completion_date":" 09/12/2022","study_txt":" Completion: 06/26/2025","study_completion_date":" 06/26/2025","last_update_posted":"2024-06-10"},{"id":"1250c179-6562-4901-865f-17545e9bd303","acronym":"ML43171","url":"https://clinicaltrials.gov/study/NCT05306340","created_at":"2022-04-01T21:53:28.059Z","updated_at":"2024-07-02T16:34:58.786Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","source_id_and_acronym":"NCT05306340 - ML43171","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • fulvestrant • dexamethasone • exemestane • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-05"},{"id":"da3993b4-3224-43f3-abf3-1a2b44201eaf","acronym":"TINKS","url":"https://clinicaltrials.gov/study/NCT05634369","created_at":"2023-12-20T08:17:53.968Z","updated_at":"2024-07-02T16:34:37.915Z","phase":"Phase 1/2","brief_title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","source_id_and_acronym":"NCT05634369 - TINKS","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • dexamethasone • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-05"},{"id":"ef515d3d-d584-4ab7-90a2-1415e247bfbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04442022","created_at":"2021-01-18T21:22:49.510Z","updated_at":"2024-07-02T16:34:38.119Z","phase":"Phase 2/3","brief_title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04442022","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone"],"overall_status":"Recruiting","enrollment":" Enrollment 501","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-05"},{"id":"8ac311e1-51b9-4db1-ab2f-31550ca1d3bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762381","created_at":"2021-02-21T13:52:19.658Z","updated_at":"2024-07-02T16:34:59.057Z","phase":"","brief_title":"Dexamethasone and Robotic-assisted Hysterectomy","source_id_and_acronym":"NCT04762381","lead_sponsor":"Herning Hospital","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone"],"overall_status":"Completed","enrollment":" Enrollment 109","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 02/06/2024","primary_completion_date":" 02/06/2024","study_txt":" Completion: 02/06/2024","study_completion_date":" 02/06/2024","last_update_posted":"2024-06-04"},{"id":"89d85ce4-ea03-4058-ba7a-82fb284611ca","acronym":"EPCORE NHL-2","url":"https://clinicaltrials.gov/study/NCT04663347","created_at":"2021-06-15T19:53:31.777Z","updated_at":"2024-07-02T16:34:59.645Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","source_id_and_acronym":"NCT04663347 - EPCORE NHL-2","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • dexamethasone • bendamustine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 662","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2024-05-31"},{"id":"309336fe-c633-4941-857b-be9dfdd1dccf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03114865","created_at":"2021-01-18T15:20:34.297Z","updated_at":"2024-07-02T16:35:00.894Z","phase":"Phase 1/2","brief_title":"A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance","source_id_and_acronym":"NCT03114865","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-27"},{"id":"40f5121b-bb06-4c08-8167-45765aada070","acronym":"KCP-8602-801","url":"https://clinicaltrials.gov/study/NCT02649790","created_at":"2021-01-17T17:34:58.356Z","updated_at":"2024-07-02T16:35:00.978Z","phase":"Phase 1/2","brief_title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","source_id_and_acronym":"NCT02649790 - KCP-8602-801","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • dexamethasone • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 277","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-24"}]